TSG101 and ovarian carcinoma: In ovarian cancer cells, increased TSG101 levels upregulate CBP/p300-interacting transactivator with ED-rich tail 2 (CITED2) and hypoxia-inducible factor 1α (HIF-1α), while downregulating tumor suppressor p21 and subsequently promoting cell growth and survival [37,40].